Elan’s Martin Aims To Set The Record Straight About Recent Buying Spree
This article was originally published in The Pink Sheet Daily
Executive Summary
Changes at the Irish company have sparked a swath of media speculation and analyst interest. Elan CEO Kelly Martin used a recent fireside chat in New York to paint a clearer picture of what is going on at the company and the rationale behind its recently proposed M&A.
You may also be interested in...
Elan’s Saga Comes To A Close With Perrigo’s $8.6 Billion Bid
Perrigo is using Elan’s beneficial tax rates to launch its international expansion and the royalty stream from Tysabri to help fund those M&A endeavors, but is not dramatically changing its OTC focus.
Elan’s Saga Comes To A Close With Perrigo’s $8.6 Billion Bid
Perrigo is using Elan’s beneficial tax rates to launch its international expansion and the royalty stream from Tysabri to help fund those M&A endeavors, but is not dramatically changing its OTC focus.
Elan Shareholder Vote Indicates Lack Of Faith In Management’s Decisions
The Irish company’s investors voted against its plans to transform the company, but have left its suitor, Royalty Pharma, with few options to continue pursuing the bid.